GC 502
Alternative Names: GC-502Latest Information Update: 28 Oct 2024
At a glance
- Originator Gracell Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In adolescents, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral, Infusion)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral, Infusion)
- 22 Feb 2024 Gracell Biotechnology has been acquired by AstraZeneca